Background
Methods
Patients
Treatment
Clinical and laboratory tests
Statistics
Results
Baseline patient characteristics
RA (n = 64) | PsA (n = 29) | AS (n = 20) | MTX (n = 49) | anti-TNF ± MTX (n = 64) | |
---|---|---|---|---|---|
Age (years) |
57 (28–79)
|
50 (23–78)
¥
|
49 (30–72)
ф
| 56 (28–79) | 55 (23–75) |
Women, n (%) |
47 (73)
|
12 (41)
¥
|
4 (20)
ɸ€
| 30 (61) | 33 (52) |
Rheumatic disease duration (years) | 2 (0–30) | 3 (0–37) | 3 (0–40) |
0.10 (0–25)
|
3.7 (0–40)*
|
Disease activity | |||||
CRP (mg/L) | 8 (1–78) | 5 (1–99) | 10 (1–157) | 8 (1–99) | 6.5 (1–157) |
ESR (mm/h) |
18.5 (1–81)
|
7 (2–48)
¥
|
9.5 (2–87)
ɸ
| 14 (1–81) | 13 (2–87) |
Anti-CCP, n (%) | 39 (61) | – | – | 17 (35) | 22(34) |
Rheumatoid factor IgA, n (%) | 32 (50) | – | – | 15 (31) | 17 (27) |
Rheumatoid factor IgM, n (%) | 45 (70) | – | – | 22(45) | 23(36) |
BASDAI | – | 4.73 (0.3–9.5) | 5.1 (0.9–9.6) | 5.5 (0.3–9.3) | 5.1 (0.9–9.7) |
BASFI | – | 3.2(0–9) | 4.1 (1.1–7.6) | 3.0 (0–9) | 3.8 (0.4–8.6) |
BASMI | – | – | 3 (0–10) | – | 3 (0–10) |
DAS28 | 4.98 (2.6–7.3) | – | – | 5.2 (3.1–7.3) | 5.1(2.6–7.1) |
PtGA | 52 (5–98) | 44 (2–96) | 56 (6–96) | 52 (2–96) | 49 (6–98) |
PGA |
38 (7–73)
|
21 (0–57)
¥
|
26 (3–60)
ф
|
38 (11–73)
|
27(0–73)*
|
MHAQ | 0.65 (0–1.45) | 0.40 (0.05–1.55) | 0.43 (0–1.40) | 0.45 (1–1.55) | 0.50 (0–1.40) |
Treatment, n (%) | |||||
Anti-TNF monotherapy |
0 (0)
|
4 (14)
¥
|
20 (100)
ɸ€
|
0
|
24 (38)*
|
MTX monotherapy |
34 (53)
|
15 (52)
|
0 (0)
ɸ€
|
49 (100)
|
0 (0)*
|
Anti-TNF ± MTX |
30 (47)
|
10 (34)
|
0 (0)
ɸ€
|
0 (0)
|
40 (62)*
|
Beta-blockers | 5 (8) | 1 (3) | 4 (20) | 4 (8) | 6 (9) |
Calcium antagonists | 5 (8) | 2 (7) | 2 (10) | 2 (4) | 7 (11) |
ACE inhibitors | 6 (9) | 1 (3) | 2 (10) | 4 (8) | 5 (8) |
NSAIDs |
47 (73)
|
14 (48)
¥
|
14 (70)
| 35 (71) | 40 (62) |
Coxibs | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 1 (2) |
Statins |
12 (19)
|
1 (3)
¥
|
7 (35)
€
| 7 (14) | 13 (20) |
Acetyl salicylic acid | 6 (9) | 2 (7) | 3 (15) | 6 (12) | 5 (8) |
Warfarin | 0 (0) | 0 (0) |
1 (5)
€
| 0 (0) | 1 (2) |
Glucocorticoids |
17 (27)
|
3 (10)
¥
|
2 (10)
ɸ
|
8 (16)
|
15 (23)*
|
RA (n = 64) | PsA (n = 29) | AS (n = 20) | MTX (n = 49) | anti-TNF ± MTX (n = 6) | |
---|---|---|---|---|---|
Cardiovascular risk factors | |||||
Hypertension | 17 (27) | 7 (24) | 6 (30) | 9 (18) | 21 (33) |
BMI (kg/m2), median (range) | 26 (19–41) | 26 (19–39) | 28 (22–36) | 26 (20–39) | 27 (20 – 41) |
Hyperlipidemia | 11 (17) | 3 (10) | 3 (15) | 9 (18) | 8 (12) |
Current smokers | 20 (31) | 6 (21) | 10 (50) | 15 (31) | 21 (33) |
Family history of CVD or death | 33 (52) | 13 (45) | 10 (50) | 24(50) | 32 (50) |
Diabetes | 3 (5) | 0 (0) | 1 (5) | 0 (0) | 4 (6) |
Medical history | |||||
Previous myocardial infarction | 5 (8) | 0 (0) | 2 (10) | 2 (4) | 5 (8) |
Angina pectoris | 2 (3) | 1 (3) | 2 (10) | 2 (4) | 3 (5) |
Endothelial dysfunction | |||||
RHI, median (range) | 1.89 (1.24–2.94) |
2.06 (1.45–2.94)
|
1.81 (1.37–2.72)
€
| 1.93 (1.24–2.76) | 1.82 (1.37–2.94) |
ED | 22 (34) | 9 (31) | 9 (45) | 18 (37) | 22 (34) |
RHI, median (range) for patients with ED | 1.47 (1.24–1.65) | 1.56 (1.45–1.64) | 1.52 (1.37–1.64) | 1.49 (1.24–1.63) | 1.52 (1.37–1.65) |
RHI improvement in patients with ED
Effect of MTX and anti-TNF ± MTX on RHI in patients with ED
Linear regression analysis
Unadjusted | Adjusted | |||||
---|---|---|---|---|---|---|
Beta |
P
| 95% CI | Beta |
P
| 95% CI | |
Female gender |
0.492
|
0.011
|
0.118 to 0.865
|
0.621
|
0.004
|
0.220 to 1.022
|
Age | –0.004 | 0.669 | –0.024 to 0.016 | –0.001 | 0.919 | –0.021 to 0.019 |
Anti-TNF ± MTX |
–0.505
|
0.008
|
–0.866 to –0.143
|
–0.448
|
0.032
|
–0.855 to –0.041
|
RDD |
–0.026
|
0.033
|
–0.049 to –0.002
| –0.024 | 0.068 | –0.050 to 0.002 |
PsA | –0.067 | 0.779 | –0.550 to 0.416 | 0.064 | 0.733 | –0.386 to 0.514 |
AS | –0.267 | 0.242 | –0.722 to 0.188 | 0.219 | 0.419 | –0.327 to 0.765 |
CRP | –0.004 | 0.523 | –0.017 to 0.009 | |||
ESR | –0.002 | 0.771 | –0.017 to 0.013 | |||
PTX3 | –0.071 | 0.255 | –0.194 to 0.053 | |||
PGA | 0.008 | 0.160 | –0.003 to 0.019 | |||
PtGA | –0.001 | 0.824 | –0.008 to 0.006 | |||
MHAQ | –0.328 | 0.332 | –1.006 to 0.349 | |||
NSJ | –0.150 | 0.050 | –0.299 to 0.000 |